#None #Breast Cancer #ScreenPoint Medical #Biomediq A/S

ScreenPoint Medical Strengthens Breast Cancer Risk Assessment with Biomediq Acquisition

In a significant move towards improving breast cancer diagnostics, ScreenPoint Medical recently announced the acquisition of Biomediq A/S. This strategic partnership aims to bolster ScreenPoint’s capabilities in assessing breast cancer risk through advanced imaging technologies. Biomediq, known for its expertise in quantitative imaging biomarkers, has been a close collaborator of ScreenPoint for over a decade. The acquisition is expected to further enhance ScreenPoint's already esteemed AI solution, Transpara, which aids radiologists in detecting cancers at earlier stages.

Enhancing Mammography Analysis

The technology developed by Biomediq analyses both 2D and 3D mammograms to provide automatic evaluations of breast cancer risk. At the core of this technology lies the Mammographic Texture Risk biomarker, which identifies tissue heterogeneity often related to both short-term and long-term cancer risks. This innovative approach is expected to greatly enhance Transpara’s functionality, providing a more comprehensive assessment of breast health.

Recent research published in the esteemed journal Radiology has shown that when combined with Biomediq's texture model, Transpara’s tools for detection and density assessment significantly improve risk prediction. The publication, entitled 'Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture,' indicated that women categorized as high risk by Transpara could potentially benefit from doubled early detection rates.

Collaborative Expertise to Drive Innovation

The first author of the mentioned study, Dr. Andreas D. Lauritzen, will join ScreenPoint’s team as the company accelerates the development of its risk assessment capabilities. This is aligned with the view of Professor Nico Karssemeijer, co-founder and Chief Scientific Officer at ScreenPoint Medical, who emphasizes the importance of risk-stratified screening to optimize mammography screening and resource allocation.

In line with this vision, the latest version of Transpara, version 2.1, has been developed with input from leading users around the globe. The upgraded algorithm not only incorporates additional training but is also designed to support automated breast density assessment. This new feature allows for comparisons of current studies with up to three prior screenings over the past six years, a temporal comparison capability that is first of its kind in the market.

The Path Ahead in Breast Cancer Screening

Moreover, the integration of Biomediq's technology promises to refine the screening process by improving the accuracy and consistency of breast cancer detection, ensuring that all women receive the best possible care. This partnership fosters a deeper commitment to enhancing radiology workflow and supporting women's health initiatives, as noted by Professor Mads Nielsen from Biomediq, who will continue to provide advisory support in the expanded ScreenPoint team.

With an impressive backing of over 35 peer-reviewed publications, Transpara is recognized as the only AI breast screening algorithm thoroughly tested in large-scale settings, demonstrating its efficacy across multiple studies evaluated by prestigious entities such as UCLA and the Norwegian Cancer Registry.

As the landscape of breast cancer risk assessment evolves, this acquisition not only underscores a significant advancement in medical technology but also highlights the ongoing commitment of both ScreenPoint Medical and Biomediq in improving breast cancer outcomes for women everywhere. Researchers have shown that up to 45% of interval cancers could potentially be identified earlier using Transpara, underscoring its importance in both facilitating workload for medical professionals and optimizing patient care.

In conclusion, the acquisition of Biomediq by ScreenPoint Medical marks a pivotal step forward in the field of breast cancer risk assessment, promising to enhance technology-driven solutions in mammography and support the early detection of breast cancer.